Trial of Amgen, Servier’s heart failure drug clears interim check

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 28, 2020 at 10:22 AM.

  1. #1 cafead, Feb 28, 2020 at 10:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via Amgen and Servier are creeping closer to a readout on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their phase 3 study passed a second futility review.

    article source
     
    Quote

Reply to Thread